What Tegmine Therapeutics does

Tegmine Therapeutics is a private, pre-clinical biotechnology company headquartered in San Francisco, California, with a research facility in South San Francisco's biotech corridor. The company develops antibody-based therapeutics that target glycoproteins — cell-surface structures characteristic of many aggressive solid cancers — with the goal of treating malignancies that lack effective targeted therapies. Its lead candidate class is built on proprietary chemistry around cancer-associated glycan modifications, an area the company describes as broadly underserved by current oncology biologics.

The company's central technology is the proprietary TegMiner™ platform, an engineered system for identifying unique cancer-specific epitopes arising from glycan modifications on glycoproteins and for generating monoclonal antibodies and antibody-drug conjugates (ADCs) against them. Pipeline products include glycoprotein-targeting antibodies intended to improve efficacy while reducing toxic side effects relative to conventional cancer therapies, and ADCs that pair these antibodies with cytotoxic payloads for currently untreatable cancers. In April 2022, Tegmine announced a collaboration with Alloy Therapeutics, under which Tegmine supplies immunogens and reagents while Alloy leads antibody discovery and validation, splitting the work along each party's core competencies in glycan targeting and antibody engineering.

Tegmine operates as a pre-revenue, partnership-driven biotech. The company has no disclosed funding rounds, investors, or revenue figures in the available data, though it offers equity compensation to employees and currently lists two open scientific positions (Research Associate in Antibody Discovery and Development; Scientist in Cell Biology) at the South San Francisco research site. Future commercialization is expected to flow through licensing agreements or co-development with pharmaceutical partners, leveraging CEO Jeff Bernstein's prior experience at Merck and Stemcentrx — including contribution to the approved V114 glycoconjugate vaccine — to advance candidates toward IND-enabling studies and eventual partnering.

Name

Tegmine Therapeutics

Legal name

Tegmine Therapeutics

Website

https://tegminetx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Tegmine Therapeutics is a private, pre-clinical biotech developing antibody therapeutics and antibody-drug conjugates that target glycoprotein modifications on solid tumors, using its proprietary TegMiner™ discovery platform and a partnership with Alloy Therapeutics.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Antibody therapeutics
• Glycoprotein targeting
• Cancer drug discovery
• Antibody-drug conjugates
• Oncology biologics

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Biopharmaceutical Development: Pre-revenue biotech company developing novel antibody therapeutics for cancer treatment. Revenue model likely based on licensing deals, co-development partnerships, and eventual product commercialization through pharmaceutical partners.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Tegmine Therapeutics develops antibody-based therapeutics that target glycoproteins, a hallmark of solid cancers. The company uses its proprietary TegMiner™ platform to discover unique cancer-specific epitopes on glycoproteins and to engineer novel monoclonal antibodies and antibody-drug conjugates (ADCs) aimed at treating solid cancers with high unmet medical need while reducing toxic side effects.

Product overview

Tegmine Therapeutics is a biotechnology company operating with a single unified discovery platform called TegMiner™, which enables the identification of unique cancer epitopes on glycoproteins. The company's product portfolio consists of a pipeline of therapeutic candidates including glycoprotein-targeting antibodies and antibody-drug conjugates (ADCs), all developed through the TegMiner platform to target cancer-related glycan modifications. The platform serves as the foundational technology enabling development of the antibody-based therapeutic pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• Glycoprotein-Targeting Antibodies Pre-clinical antibody therapeutic candidates developed on the TegMiner™ platform that target glycoproteins — a hallmark of solid cancers — to increase anti-tumor efficacy while reducing toxic side effects relative to conventional cancer therapies. Targeted at pharmaceutical and biotech partners for licensing or co-development.
• Antibody-Drug Conjugates (ADCs) Therapeutic ADC candidates that combine Tegmine's glycoprotein-targeting antibodies with cytotoxic payloads, intended to enable targeted delivery of cell-killing agents to solid tumors while sparing healthy tissue. Targeted at pharmaceutical and biotech partners for licensing or co-development.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Alloy TherapeuticscoreStrategic or Co-development Partner · 6 April 2022Tegmine Therapeutics announced a collaboration with Alloy Therapeutics to develop antibody therapeutics targeting cancer-related glycan modifications. Under the agreement, Tegmine will produce immunogens and reagents while Alloy will lead antibody discovery and validation efforts. This partnership leverages each company's core competencies in glycan targeting and antibody discovery to advance novel cancer therapeutics.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• Bolt Biotherapeutics: Clinical-stage biotech developing ADCs and immune-stimulating antibody conjugates for solid tumors. Highly comparable to Tegmine's glycoprotein-targeting ADC pipeline and oncology-focused discovery model, though operating at a more advanced clinical stage.
• Pyxis Oncology: ADC-focused oncology company developing antibody-drug conjugates for solid tumors. Direct comparability in modality (ADCs) and therapeutic area (solid tumor oncology), with overlapping glycoprotein/antibody discovery capabilities.
• ProfoundBio: Pre-clinical and early-clinical biotech developing ADCs and antibody therapeutics for cancer. Comparable platform approach and oncology focus, useful as a peer for capital-efficient pre-clinical ADC builders.
• Mersana Therapeutics: Clinical-stage ADC company with proprietary platforms (Dolasynthen, Immunosynthen). Strong direct comparability on ADC modality and oncology indications, despite being at a more advanced stage than Tegmine.

Broad incumbents

• ImmunoGen (AbbVie): Pioneer in ADC development (now part of AbbVie) with multiple approved and clinical-stage ADCs. Represents the incumbent benchmark against which Tegmine's emerging ADC pipeline will be compared for licensing and partnership value.
• Seagen (Pfizer): Global ADC leader (acquired by Pfizer in 2023) with multiple approved oncology ADCs. Major incumbent that defines the strategic and competitive landscape for ADC-focused startups like Tegmine.
• Daiichi Sankyo: Japanese pharma leader in next-generation ADCs (Enhertu, Datroway). Sets the bar for ADC efficacy and global partnership economics, making it the most relevant incumbent peer for an ADC startup.
• Genmab: Pioneer in monoclonal antibody therapeutics (Darzalex, with Janssen). Broad incumbent whose antibody discovery and licensing playbook is the model against which Tegmine's mAb pipeline should be benchmarked.

Emerging players

• Mythic Therapeutics: Pre-clinical/early-clinical biotech developing antibody therapeutics for solid tumors using a proprietary platform. Highly comparable stage and platform approach to Tegmine, useful as a peer for early-stage antibody oncology developers.
• Werewolf Therapeutics: Clinical-stage oncology biotech developing engineered antibody-based therapeutics (PREDATOR platform) for solid tumors. Comparable in therapeutic area (solid tumor oncology) and platform-driven antibody approach, despite being at a more advanced stage.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tegmine-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tegmine Therapeutics